Halochondrin B Analogs, Microtubule Inhibitor

The class "Halochondrin B Analogs, Microtubule Inhibitor" refers to an antineoplastic drug grouping—most commonly represented by the synthetic analog eribulin—derived from the natural marine product halichondrin B

The class "Halochondrin B Analogs, Microtubule Inhibitor" refers to an antineoplastic drug grouping—most commonly represented by the synthetic analog eribulin—derived from the natural marine product halichondrin B In clinical oncology, they are primarily utilized for the treatment of advanced or metastatic breast cancer previously treated with standard chemotherapy regimens, as well as unresectable or metastatic liposarcoma

The class "Halochondrin B Analogs, Microtubule Inhibitor" refers to an antineoplastic drug grouping—most commonly represented by the synthetic analog eribulin—derived from the natural marine product halichondrin B. Mechanistically, these agents act as non-taxane microtubule dynamics inhibitors that selectively block the growth phase of microtubules without altering the shortening phase, thereby sequestering tubulin into nonproductive aggregates, arresting the cell cycle in the G2/M phase, and tr...

The class "Halochondrin B Analogs, Microtubule Inhibitor" refers to an antineoplastic drug grouping—most commonly represented by the synthetic analog eribulin—derived from the natural marine product halichondrin B. Mechanistically, these agents act as non-taxane microtubule dynamics inhibitors that selectively block the growth phase of microtubules without altering the shortening phase, thereby sequestering tubulin into nonproductive aggregates, arresting the cell cycle in the G2/M phase, and tr...

The class "Halochondrin B Analogs, Microtubule Inhibitor" refers to an antineoplastic drug grouping—most commonly represented by the synthetic analog eribulin—derived from the natural marine product halichondrin B. Mechanistically, these agents act as non-taxane microtubule dynamics inhibitors that selectively block the growth phase of microtubules without altering the shortening phase, thereby sequestering tubulin into nonproductive aggregates, arresting the cell cycle in the G2/M phase, and tr...

In clinical oncology, they are primarily utilized for the treatment of advanced or metastatic breast cancer previously treated with standard chemotherapy regimens, as well as unresectable or metastatic liposarcoma